Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer

Cancer Biomarkers

Volumn 13, Issue 5, 2013, Pages 359-366

  Kang, Melissa ^a   Shen, Xiang J ^a   Kim, Sangmi ^b   Araujo Perez, Felix ^a   Galanko, Joseph A ^a   Martin, Chris F ^a   Sandler, Robert S ^a   Keku, Temitope O ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

African Americans; BRAF; Colorectal cancer; KRAS; PIK3CA

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BODY MASS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CAUCASIAN; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MIDDLE AGED; MORTALITY; MUTATION RATE; OBESITY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE DIFFERENCE; SMOKING; SOMATIC MUTATION; TISSUE MICROARRAY;

AFRICAN-AMERICANS; BRAF; COLORECTAL CANCER; KRAS; PIK3CA;

AFRICAN AMERICANS; AGED; COHORT STUDIES; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RISK; TISSUE ARRAY ANALYSIS;

EID: 84892933344     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-130366     Document Type: Article

References (41)

1. D. Alexander, C. Chatla, E. Funkhouser, S. Meleth, W.E. Grizzle, and U. Manne, Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma, Cancer 101 (2004), 66-76
2. J.Z. Ayanian, E.A. Chrischilles, R.H. Fletcher, M.N. Fouad, D.P. Harrington, K.L. Kahn, C.I. Kiefe, J. Lipscomb, J.L. Malin, A.L. Potosky, D.T. Provenzale, R.S. Sandler, M. van Ryn, R.B. Wallace, J.C. Weeks, and D.W. West, Understanding cancer treatment and outcomes. the Cancer Care Outcomes Research and Surveillance Consortium, J Clin Oncol 22 (2004), 2992-2996
3. A. Bardelli and S. Siena, Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer, J Clin Oncol 28 (2010), 1254-1261
4. C. Bokemeyer, I. Bondarenko, A. Makhson, J.T. Hartmann, J. Aparicio, F. de Braud, S. Donea, H. Ludwig, G. Schuch, C. Stroh, A.H. Loos, A. Zubel, and P. Koralewski, Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer, J Clin Oncol 27 (2009), 663-671
5. C.R. Boland, S.N. Thibodeau, S.R. Hamilton, D. Sidransky, J.R. Eshleman, R.W. Burt, S.J. Meltzer, M.A. Rodriguez-Bigas, R. Fodde, G.N. Ranzani, and S. Srivastava, A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition. Development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Res 58 (1998), 5248-5257
6. H. Brim, P. Mokarram, F. Naghibalhossaini, M. Saberi-Firoozi, M. Al-Mandhari, K. Al-Mawaly, R. Al-Mjeni, A. Al-Sayegh, S. Raeburn, E. Lee, F. Giardiello, D.T. Smoot, A. Vilkin, C.R. Boland, A. Goel, M. Hafezi, M. Nouraie, and H. Ashktorab, Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study, Mol Cancer 7 (2008), 68
7. L. De Mattos-Arruda, R. Dienstmann, and J. Tabernero, Development of molecular biomarkers in individualized treatment of colorectal cancer, Clin Colorectal Cancer 10 (2011), 279-289
8. F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, and A. Bardelli, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer, J Clin Oncol 26 (2008), 5705-5712
9. W. Dietmaier, S.Wallinger, T. Bocker, F. Kullmann, R. Fishel, and J. Ruschoff, Diagnostic microsatellite instability. definition and correlation with mismatch repair protein expression, Cancer Res 57 (1997), 4749-4756
10. C.A. Doubeni, A.O. Laiyemo, J.M.Major, M. Schootman, M. Lian, Y. Park, B.I. Graubard, A.R. Hollenbeck, and R. Sinha, Socioeconomic status and the risk of colorectal cancer. An analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study, Cancer 118 (2012), 3636-3644
11. P. Gulhati, Y.Y. Zaytseva, J.D. Valentino, P.D. Stevens, J.T. Kim, T. Sasazuki, S. Shirasawa, E.Y. Lee, H.L. Weiss, J. Dong, T. Gao, and B.M. Evers, Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA, Carcinogenesis 33 (2012), 1782-1790
12. Y. Hashiguchi, K. Hase, H. Ueno, E. Shinto, Y. Naito, Y. Kajiwara, T. Kuroda, J. Yamamoto, and H.Mochizuki, Impact of race/ethnicity on prognosis in patients who underwent surgery for colon cancer. analysis for white, African, and East Asian Americans, Ann Surg Oncol 19 (2012), 1517-1528
13. R.B. Hines and T.W. Markossian, Differences in late-stage diagnosis, treatment, and colorectal cancer-related death between rural and urban African Americans and whites in Georgia, J Rural Health 28 (2012), 296-305
14. M.F. Kalady, K.L. Dejulius, J.A. Sanchez, A. Jarrar, X. Liu, E.Manilich, M. Skacel, and J.M. Church, BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis, Dis Colon Rectum 55 (2012), 128-133
15. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, C.J. O'Callaghan, D. Tu, N.C. Tebbutt, R.J. Simes, H. Chalchal, J.D. Shapiro, S. Robitaille, T.J. Price, L. Shepherd, H.J. Au, C. Langer, M.J. Moore, and J.R. Zalcberg, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med 359 (2008), 1757-1765
16. S. Kato, S. Iida, T. Higuchi, T. Ishikawa, Y. Takagi, M. Yasuno, M. Enomoto, H. Uetake, and K. Sugihara, PIK3CA mutation is predictive of poor survival in patients with colorectal cancer, Int J Cancer 121 (2007), 1771-1778
17. J. Kauh, O.W. Brawley, and M. Berger, Racial disparities in colorectal cancer, Curr Probl Cancer 31 (2007), 123-133
18. K. Kumar, H. Brim, F. Giardiello, D.T. Smoot, M. Nouraie, E.L. Lee, and H. Ashktorab, Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans, Clin Cancer Res 15 (2009), 1155-1161
19. H. Le, A. Ziogas, S.M. Lipkin, and J.A. Zell, Effects of socioeconomic status and treatment disparities in colorectal cancer survival, Cancer Epidemiol Biomarkers Prev 17 (2008), 1950-1962
20. V.E. Lemmens, A.H. van Halteren, M.L. Janssen-Heijnen, G. Vreugdenhil, O.J. Repelaer van Driel, and J.W. Coebergh, Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity, Ann Oncol 16 (2005), 767-772
21. X. Liao, P. Lochhead, R. Nishihara, T.Morikawa, A. Kuchiba, M. Yamauchi, Y. Imamura, Z.R. Qian, Y. Baba, K. Shima, R. Sun, K. Nosho, J.A. Meyerhardt, E. Giovannucci, C.S. Fuchs, A.T. Chan, and S. Ogino, Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival, N Engl JMed 367 (2012), 1596-1606
22. X. Liao, T. Morikawa, P. Lochhead, Y. Imamura, A. Kuchiba, M. Yamauchi, K. Nosho, Z.R. Qian, R. Nishihara, J.A. Meyerhardt, C.S. Fuchs, and S. Ogino, Prognostic role of PIK3CA mutation in colorectal cancer. cohort study and literature review, Clin Cancer Res 18 (2012), 2257-2268
23. C. Mao, Z.Y. Yang, X.F. Hu, Q. Chen, and J.L. Tang, PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer. A systematic review and metaanalysis, Ann Oncol 23 (2012), 1518-1525
24. S. Ogino, K. Nosho, G.J. Kirkner, K. Shima, N. Irahara, S. Kure, A.T. Chan, J.A. Engelman, P. Kraft, L.C. Cantley, E.L. Giovannucci, and C.S. Fuchs, PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer, J Clin Oncol 27 (2009), 1477-1484
25. S. Ogino, K. Shima, J.A. Meyerhardt, N.J. McCleary, K. Ng, D. Hollis, L.B. Saltz, R.J. Mayer, P. Schaefer, R. Whittom, A. Hantel, A.B. Benson, 3rd, D. Spiegelman, R.M. Goldberg, M.M. Bertagnolli, and C.S. Fuchs, Predictive and prognostic roles of BRAF mutation in stage III colon cancer. Results from intergroup trial CALGB 89803, Clin Cancer Res18 (2012), 890-900
26. A.I. Phipps, D.D. Buchanan, K.W. Makar, A.N. Burnett-Hartman, A.E. Coghill, M.N. Passarelli, J.A. Baron, D.J. Ahnen, A.K. Win, J.D. Potter, and P.A. Newcomb, BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics, Cancer Epidemiol Biomarkers Prev 21 (2012), 1792-1798
27. B.N. Polite, A. Sing, D.J. Sargent, A. Grothey, J. Berlin, M. Kozloff, and S. Feng, Exploring racial differences in outcome and treatment for metastatic colorectal cancer. Results from a large prospective observational cohort study (BRiTE), Cancer 118 (2012), 1083-1090
28. C. Rosty, J.P. Young, M.D.Walsh, M. Clendenning, R.J.Walters, S. Pearson, E. Pavluk, B. Nagler, D. Pakenas, J.R. Jass, M.A. Jenkins, A.K.Win, M.C. Southey, S. Parry, J.L. Hopper, G.G. Giles, E.Williamson, D.R. English, and D.D. Buchanan, Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features, Mod Pathol 26 (2013), 825-834
29. A.D. Roth, S. Tejpar, M. Delorenzi, P. Yan, R. Fiocca, D. Klingbiel, D. Dietrich, B. Biesmans, G. Bodoky, C. Barone, E. Aranda, B. Nordlinger, L. Cisar, R. Labianca, D. Cunningham, E. Van Cutsem, and F. Bosman, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer. results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol 28 (2010), 466-474
30. G. Safaee Ardekani, S.M. Jafarnejad, L. Tan, A. Saeedi, and G. Li, The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma. A Systematic Review and Meta-Analysis, PLoS One 7 (2012), e47054
31. A. Sartore-Bianchi, M. Martini, F. Molinari, S. Veronese, M. Nichelatti, S. Artale, F. Di Nicolantonio, P. Saletti, S. De Dosso, L.Mazzucchelli, M. Frattini, S. Siena, and A. Bardelli, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies, Cancer Res 69 (2009), 1851-1857
32. J. Satia-Abouta, J.A. Galanko, C.F. Martin, A. Ammerman, and R.S. Sandler, Food groups and colon cancer risk in African-Americans and Caucasians, Int J Cancer 109 (2004), 728-736
33. A. Sood, D. McClain, R. Maitra, A. Basu-Mallick, R. Seetharam, A. Kaubisch, L. Rajdev, J.M. Mariadason, K. Tanaka, and S. Goel, PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to antiepidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer, Clin Colorectal Cancer 11 (2012), 143-150
34. B.E. Sylvester, D. Huo, A. Khramtsov, J. Zhang, R.V. Smalling, S. Olugbile, B.N. Polite, and O.I. Olopade, Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution, Clin Cancer Res 18 (2012), 350-359
35. E. Van Cutsem, C.H. Kohne, E. Hitre, J. Zaluski, C.R. Chang Chien, A. Makhson, G. D'Haens, T. Pinter, R. Lim, G. Bodoky, J.K. Roh, G. Folprecht, P. Ruff, C. Stroh, S. Tejpar, M. Schlichting, J. Nippgen, and P. Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med 360 (2009), 1408-1417
36. E. Vilar and S.B. Gruber, Microsatellite instability in colorectal cancer-the stable evidence, Nat Rev Clin Oncol 7 (2010), 153-162
37. A. White, S.W. Vernon, L. Franzini, and X.L. Du, Racial disparities in colorectal cancer survival. To what extent are racial disparities explained by differences in treatment, tumor characteristics, or hospital characteristics? Cancer 116 (2010), 4622-4631
38. M. Yamauchi, P. Lochhead, T. Morikawa, C. Huttenhower, A.T. Chan, E. Giovannucci, C. Fuchs, and S. Ogino, Colorectal cancer. A tale of two sides or a continuum? Gut 61 (2012), 794-797
39. M. Yamauchi, T. Morikawa, A. Kuchiba, Y. Imamura, Z.R. Qian, R. Nishihara, X. Liao, L. Waldron, Y. Hoshida, C. Huttenhower, A.T. Chan, E. Giovannucci, C. Fuchs, and S. Ogino, Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum, Gut 61 (2012), 847-854
40. G. Yothers, D.J. Sargent, N. Wolmark, R.M. Goldberg, M.J. O'Connell, J.K. Benedetti, L.B. Saltz, J.J. Dignam, and A.W. Blackstock, Outcomes among black patients with stage II and III colon cancer receiving chemotherapy. An analysis of ACCENT adjuvant trials, J Natl Cancer Inst 103 (2011), 1498-1506
41. H. Yuhara, C. Steinmaus, S.E. Cohen, D.A. Corley, Y. Tei, and P.A. Buffler, Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol 106(2011), 1911-1921; quiz 1922